$AKBA
Akebia Therapeutics, Inc.

2020 Q1 Form 10-Q Financial Statement

#000156459020021255 Filed on May 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $88.48M $72.67M
YoY Change 21.76% 58.31%
Cost Of Revenue $27.71M $31.26M
YoY Change -11.34%
Gross Profit $60.77M $41.41M
YoY Change 46.74%
Gross Profit Margin 68.68% 56.99%
Selling, General & Admin $37.98M $34.29M
YoY Change 10.77% 280.0%
% of Gross Profit 62.51% 82.81%
Research & Development $81.23M $82.35M
YoY Change -1.36% 34.11%
% of Gross Profit 133.68% 198.87%
Depreciation & Amortization $525.0K $439.0K
YoY Change 19.59% 120.6%
% of Gross Profit 0.86% 1.06%
Operating Expenses $119.9M $117.4M
YoY Change 2.14% 66.66%
Operating Profit -$59.13M -$75.97M
YoY Change -22.17% 210.1%
Interest Expense -$1.972M $869.0K
YoY Change -326.93% -19.24%
% of Operating Profit
Other Income/Expense, Net -$1.622M $791.0K
YoY Change -305.06% -26.76%
Pretax Income -$60.75M -$75.18M
YoY Change -19.2% 221.03%
Income Tax $0.00 -$2.757M
% Of Pretax Income
Net Earnings -$60.75M -$72.42M
YoY Change -16.12% 209.25%
Net Earnings / Revenue -68.66% -99.66%
Basic Earnings Per Share
Diluted Earnings Per Share -$472.7K -$618.3K
COMMON SHARES
Basic Shares Outstanding 129.9M 117.1M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $115.4M $168.0M
YoY Change -31.33% -51.91%
Cash & Equivalents $115.4M $62.74M
Short-Term Investments $0.00 $105.3M
Other Short-Term Assets $8.700M $15.60M
YoY Change -44.23% 92.59%
Inventory $111.9M $115.2M
Prepaid Expenses
Receivables $104.9M $48.40M
Other Receivables $0.00 $0.00
Total Short-Term Assets $340.8M $347.2M
YoY Change -1.86% -20.55%
LONG-TERM ASSETS
Property, Plant & Equipment $9.855M $41.90M
YoY Change -76.48% 1032.43%
Goodwill $55.05M $55.05M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $71.92M $128.1M
YoY Change -43.85% 6304.15%
Total Long-Term Assets $447.0M $543.6M
YoY Change -17.78% 9436.72%
TOTAL ASSETS
Total Short-Term Assets $340.8M $347.2M
Total Long-Term Assets $447.0M $543.6M
Total Assets $787.7M $890.8M
YoY Change -11.57% 101.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $54.38M $15.23M
YoY Change 257.15% -14.94%
Accrued Expenses $124.9M $137.8M
YoY Change -9.37% 155.19%
Deferred Revenue $34.89M $49.58M
YoY Change -29.64%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $214.2M $202.6M
YoY Change 5.7% 33.83%
LONG-TERM LIABILITIES
Long-Term Debt $76.07M $0.00
YoY Change
Other Long-Term Liabilities $101.1M $117.9M
YoY Change -14.25% 25.16%
Total Long-Term Liabilities $76.07M $117.9M
YoY Change -35.48% 25.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $214.2M $202.6M
Total Long-Term Liabilities $76.07M $117.9M
Total Liabilities $290.2M $324.4M
YoY Change -10.54% 32.08%
SHAREHOLDERS EQUITY
Retained Earnings -$854.8M
YoY Change
Common Stock $1.251B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $396.4M $566.4M
YoY Change
Total Liabilities & Shareholders Equity $787.7M $890.8M
YoY Change -11.57% 101.22%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$60.75M -$72.42M
YoY Change -16.12% 209.25%
Depreciation, Depletion And Amortization $525.0K $439.0K
YoY Change 19.59% 120.6%
Cash From Operating Activities -$89.59M -$137.9M
YoY Change -35.05% 578.45%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $1.928M
YoY Change -100.0% 551.35%
Acquisitions
YoY Change
Other Investing Activities $250.0K $112.4M
YoY Change -99.78% 782.95%
Cash From Investing Activities $245.0K $110.5M
YoY Change -99.78% 788.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $57.35M -14.45M
YoY Change -496.95% -115.06%
NET CHANGE
Cash From Operating Activities -$89.59M -137.9M
Cash From Investing Activities $245.0K 110.5M
Cash From Financing Activities $57.35M -14.45M
Net Change In Cash -$32.00M -41.90M
YoY Change -23.64% -147.61%
FREE CASH FLOW
Cash From Operating Activities -$89.59M -$137.9M
Capital Expenditures $0.00 $1.928M
Free Cash Flow -$89.59M -$139.9M
YoY Change -35.94% 578.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4989000
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3949000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3444000
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 us-gaap Lessee Operating Lease Existence Of Residual Value Guarantee
LesseeOperatingLeaseExistenceOfResidualValueGuarantee
false
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
245 First Street
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Entity File Number
EntityFileNumber
001-36352
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8756903
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
CY2020Q1 dei City Area Code
CityAreaCode
617
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
871-2098
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115374000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
72666000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18613000
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
22157000
CY2020Q1 us-gaap Assets
Assets
787719000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
54379000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
124887000
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
34886000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
39830000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
214152000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
208118000
CY2020Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
42799000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
33120000
CY2020Q1 us-gaap Goodwill
Goodwill
55053000
CY2020Q1 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
282112000
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
71917000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
245000
CY2020Q1 us-gaap Inventory Net
InventoryNet
111854000
CY2019Q4 us-gaap Inventory Net
InventoryNet
116349000
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
104872000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
38864000
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8656000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6626000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
340756000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
309533000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9855000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10380000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28026000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
29038000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26207000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27528000
CY2020Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
1740000
CY2019Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1650000
CY2020Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
76072000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
75805000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1251164000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1188810000
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
130251440
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
130251440
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
121674568
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
121674568
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-854801000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-794054000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
396364000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
394757000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
787719000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
771201000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
88478000
CY2020Q1 akba Amortization Of Intangible Assets Product
AmortizationOfIntangibleAssetsProduct
9100000
CY2019Q1 akba Amortization Of Intangible Assets Product
AmortizationOfIntangibleAssetsProduct
9100000
CY2020Q1 us-gaap Cost Of Revenue
CostOfRevenue
27713000
CY2019Q1 us-gaap Cost Of Revenue
CostOfRevenue
31257000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81231000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
82351000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37983000
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34291000
CY2020Q1 akba License Expense
LicenseExpense
676000
CY2019Q1 akba License Expense
LicenseExpense
736000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
119890000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
117378000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-59125000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-75969000
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1972000
CY2019Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
869000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
350000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-78000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-60747000
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-75178000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2757000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-60747000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-72421000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
128395163
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
117063352
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-60747000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-72421000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
225000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60747000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72196000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
635928000
CY2019Q1 akba Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan
StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
188000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
365000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2094000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
225000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-72421000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
566379000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
394757000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
56575000
CY2020Q1 akba Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan
StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
451000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4916000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
412000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
396364000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-60747000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-72421000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-60747000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
525000
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
439000
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9100000
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9100000
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
477000
CY2020Q1 akba Noncash Interest Expense
NoncashInterestExpense
437000
CY2019Q1 akba Noncash Interest Expense
NoncashInterestExpense
169000
CY2020Q1 akba Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
-647000
CY2019Q1 akba Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
-614000
CY2020Q1 akba Fair Value Write Up Of Inventory Sold
FairValueWriteUpOfInventorySold
11180000
CY2019Q1 akba Fair Value Write Up Of Inventory Sold
FairValueWriteUpOfInventorySold
14586000
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
139000
CY2019Q1 us-gaap Inventory Write Down
InventoryWriteDown
1664000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4916000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2094000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2757000
CY2020Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
90000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
66008000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
31769000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8163000
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
16064000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1898000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-46000
CY2019Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-719000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
20470000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-20746000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4209000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-17500000
CY2020Q1 akba Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
445000
CY2019Q1 akba Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
549000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4735000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6218000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89589000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-137929000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1928000
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
245000
CY2019Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
78691000
CY2019Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
33710000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
245000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
110473000
CY2020Q1 akba Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
56485000
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
451000
CY2019Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
188000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
412000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
365000
CY2019Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
15000000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57348000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14447000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31996000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41903000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
149804000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
107099000
CY2020Q1 akba Deferred Unpaid Offering Costs
DeferredUnpaidOfferingCosts
90000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117808000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65196000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65196000
CY2020Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">1. Nature of Organization and Operations</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Akebia Therapeutics, Inc., referred to as Akebia or the Company, was incorporated in the State of Delaware in 2007. <span style="Background-color:#FFFFFF;color:#000000;">Akebia is a biopharmaceutical company with </span><span style="color:#000000;">the purpose of bettering the lives of </span><span style="Background-color:#FFFFFF;color:#000000;">people living with kidney disease. Akebia’s lead investigational product candidate, vadadustat, is an oral therapy in Phase 3 development. The Company believes vadadustat has the potential to set a new standard of care in the treatment of anemia due to CKD, acting via a novel hypoxia inducible factor, or HIF, pathway. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body, as well as other important metabolic functions. The Company’s commercial product, Auryxia<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> (ferric citrate) is currently approved by the U.S. Food and Drug Administration, or FDA, and marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with chronic kidney disease, or CKD, on dialysis, or DD-CKD, and the treatment of iron deficiency anemia, or IDA, in adult patients with CKD not on dialysis, or NDD-CKD. </span>Ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with DD-CKD and NDD-CKD under the trade name Riona<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> (ferric citrate hydrate)<span style="Background-color:#FFFFFF;color:#000000;">.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has devoted most of its resources to research and development, including its preclinical and clinical development activities, and providing general and administrative support for these operations. The Company began recording revenue from the U.S. sales of Auryxia and revenue from sublicensing rights to Auryxia in Japan to the Company’s Japanese partners <span style="Background-color:#FFFFFF;color:#000000;">Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., collectively, JT and Torii,</span> on December 12, 2018 following the consummation of a merger with <span style="Background-color:#FFFFFF;color:#000000;">Keryx Biopharmaceuticals, Inc., or Keryx, or the Merger</span>. The Company has not generated a profit to date and may never generate profits from product sales. The Company’s product candidates are subject to long development cycles, and the Company may be unsuccessful in its efforts to develop, obtain marketing approval for or market its product candidates. If the Company does not successfully commercialize any of its products or product candidates, it may be unable to achieve profitability.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s management completed its going concern assessment in accordance with ASC 205-40, <span style="font-style:italic;">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span>, or ASC 205-40. The Company believes that its cash resources will be sufficient to allow the Company to fund its current operating plan through at least the next twelve months from the filing of this Quarterly Report on Form 10-Q, as required by ASC 205-40. There can be no assurance, however, that the current operating plan will be achieved in the time frame anticipated by the Company, or that its cash resources will fund the Company’s operating plan for the period anticipated by the Company or that additional funding will be available on terms acceptable to the Company, or at all. The Company will require additional capital for the further commercialization of Auryxia and continued development and potential commercialization of the Company’s existing product candidates and would need to raise additional funds to pursue development activities related to any additional product candidates. If and until the Company can generate a sufficient amount of product revenue, the Company expects to finance future cash needs through public or private equity or debt transactions, payments from its collaborators, royalty transactions, strategic transactions, or a combination of these approaches. However, adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on attractive terms, it may be forced to delay, reduce or eliminate its research and development programs or any commercialization efforts.</p>
CY2020Q1 akba Operating Plan Sufficiently Funded By Cash Resources Period
OperatingPlanSufficientlyFundedByCashResourcesPeriod
P12M
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, operating lease assets and liabilities, derivative liabilities, other non-current liabilities, stock-based compensation expense, product and collaboration revenues including various rebates and reserves related to product sales, inventories, income taxes, intangible assets and goodwill. The Company has made estimates of the impact of COVID-19 within the unaudited condensed consolidated financial statements and there may be changes to those estimates in future periods including changes to sales, payer mix, reserves and allowances, intangible assets and goodwill. While the COVID-19 pandemic has not had a material adverse impact on the Company’s financial condition, the future impacts of the pandemic and any resulting economic impact is largely unknown and rapidly evolving.</p>
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14044000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14044000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4189000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3664000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9855000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10380000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117808000
CY2020Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115374000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62741000
CY2020Q1 us-gaap Depreciation
Depreciation
500000
CY2019Q1 us-gaap Depreciation
Depreciation
400000
CY2020Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P9Y
CY2020Q1 akba Fair Value Remeasurements To Property And Equipment
FairValueRemeasurementsToPropertyAndEquipment
0
CY2019Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
31543000
CY2020Q1 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
33822000
CY2020Q1 akba Valuation Allowances And Reserves Adjustments Related To Prior Period Sales
ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
114000
CY2020Q1 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
32428000
CY2020Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
33051000
CY2018Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
23737000
CY2019Q1 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
19832000
CY2019Q1 akba Valuation Allowances And Reserves Adjustments Related To Prior Period Sales
ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
156000
CY2019Q1 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
19743000
CY2019Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
23982000
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
34886000
CY2020Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
42799000
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
77685000
CY2020Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
10130000
CY2019Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
45179000
CY2019Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
1254000
CY2020Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
1740000
CY2020Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1841000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2278000
CY2019Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
1650000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115374000
CY2020Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
115374000
CY2020Q1 akba Cash Cash Equivalents And Short Term Investments Amortized Cost
CashCashEquivalentsAndShortTermInvestmentsAmortizedCost
115374000
CY2020Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
115374000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147449000
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
147449000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
245000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
245000
CY2019Q4 akba Cash Cash Equivalents And Short Term Investments Amortized Cost
CashCashEquivalentsAndShortTermInvestmentsAmortizedCost
147694000
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
147694000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2019Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
90000
CY2020Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
135474000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
137858000
CY2020Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
36925000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
42096000
CY2020Q1 akba Inventory Net Current And Non Current
InventoryNetCurrentAndNonCurrent
174240000
CY2019Q4 akba Inventory Net Current And Non Current
InventoryNetCurrentAndNonCurrent
182232000
CY2020Q1 us-gaap Inventory Net
InventoryNet
111854000
CY2019Q4 us-gaap Inventory Net
InventoryNet
116349000
CY2020Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
62386000
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
65883000
CY2020Q1 akba Inventory Net Current And Non Current
InventoryNetCurrentAndNonCurrent
174240000
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
100000
CY2019Q1 us-gaap Inventory Write Down
InventoryWriteDown
1700000
CY2020Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
329675000
CY2020Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
47023000
CY2020Q1 akba Finite Lived Intangible Assets Adoption Adjustment
FiniteLivedIntangibleAssetsAdoptionAdjustment
-540000
CY2020Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
282112000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
329675000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
37923000
CY2019Q4 akba Finite Lived Intangible Assets Adoption Adjustment
FiniteLivedIntangibleAssetsAdoptionAdjustment
-540000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
291212000
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
27302000
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
36401000
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
36402000
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
36401000
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
36402000
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
109204000
CY2020Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
282112000
CY2020Q1 us-gaap Goodwill
Goodwill
55100000
CY2019Q4 us-gaap Goodwill
Goodwill
55100000
CY2020Q1 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
527754000
CY2020Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
-472701000
CY2020Q1 us-gaap Goodwill
Goodwill
55053000
CY2020Q1 akba Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
54581000
CY2019Q4 akba Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
61815000
CY2020Q1 akba Accrued Product Revenue Allowances Current
AccruedProductRevenueAllowancesCurrent
31225000
CY2019Q4 akba Accrued Product Revenue Allowances Current
AccruedProductRevenueAllowancesCurrent
30552000
CY2020Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
7727000
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
12604000
CY2020Q1 akba Mtpc Supply Of Validation Drug Product
MTPCSupplyOfValidationDrugProduct
6441000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5096000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
121674568
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
121674568
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
130251440
CY2020Q1 akba Accrued Commercial Manufacturing Current
AccruedCommercialManufacturingCurrent
2694000
CY2019Q4 akba Accrued Commercial Manufacturing Current
AccruedCommercialManufacturingCurrent
2680000
CY2020Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2459000
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2713000
CY2020Q1 us-gaap Postemployment Benefits Liability Current
PostemploymentBenefitsLiabilityCurrent
452000
CY2019Q4 us-gaap Postemployment Benefits Liability Current
PostemploymentBenefitsLiabilityCurrent
725000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10263000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9549000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
124887000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
129071000
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7140000
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
30354000
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
42506000
CY2020Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
80000000
CY2020Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
3928000
CY2020Q1 us-gaap Long Term Debt
LongTermDebt
76072000
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
130251440
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 akba Lessee Operating Lease Liability Payments Due Net Year Four
LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour
5040000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5116000
CY2020Q1 akba Lessee Operating Lease Liability Payments Due Net Year Five
LesseeOperatingLeaseLiabilityPaymentsDueNetYearFive
5116000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5347000
CY2020Q1 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
307000
CY2020Q1 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
1328000
CY2020Q1 akba Lessee Operating Lease Liability Payments Net Reminder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear
3492000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7064000
CY2020Q1 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
1797000
CY2020Q1 akba Lessee Operating Lease Liability Payments Due Net Year Two
LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo
5267000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6735000
CY2020Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
24958932
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
21403890
CY2020Q1 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
1824000
CY2020Q1 akba Lessee Operating Lease Liability Payments Due Net Year Three
LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree
4911000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4916000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2094000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4916000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2094000
CY2020Q1 us-gaap Lessee Operating Lease Residual Value Guarantee Description
LesseeOperatingLeaseResidualValueGuaranteeDescription
The lease agreements do not contain residual value guarantees.
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1700000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1700000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1700000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1700000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4820000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
8818000
CY2020Q1 akba Lessee Operating Lease Liability Payments Due Net After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFive
8818000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
37900000
CY2020Q1 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
5256000
CY2020Q1 akba Lessee Operating Lease Liability Payments Due Net
LesseeOperatingLeaseLiabilityPaymentsDueNet
32644000
CY2020Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
67400000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
37900000
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6596000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
31304000
CY2020Q1 akba Supply Agreement Description
SupplyAgreementDescription
The Esteve Agreement has an initial term of four years, beginning April 9, 2019 and ending April 9, 2023
CY2019Q2 akba Initial Term Of Supply Agreement
InitialTermOfSupplyAgreement
four years
CY2020Q1 akba Purchase Committed Program Remaining Contract Costs
PurchaseCommittedProgramRemainingContractCosts
41100000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16617256
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12830125

Files In Submission

Name View Source Status
0001564590-20-021255-index-headers.html Edgar Link pending
0001564590-20-021255-index.html Edgar Link pending
0001564590-20-021255.txt Edgar Link pending
0001564590-20-021255-xbrl.zip Edgar Link pending
akba-10q_20200331.htm Edgar Link pending
akba-10q_20200331_htm.xml Edgar Link completed
akba-20200331.xsd Edgar Link pending
akba-20200331_cal.xml Edgar Link unprocessable
akba-20200331_def.xml Edgar Link unprocessable
akba-20200331_lab.xml Edgar Link unprocessable
akba-20200331_pre.xml Edgar Link unprocessable
akba-ex101_298.htm Edgar Link pending
akba-ex311_8.htm Edgar Link pending
akba-ex312_7.htm Edgar Link pending
akba-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending